2024-10-23T12:15:06-05:00 2024-06-30 363963131 MANN WEITZ & ASSOCIATES LLC 570 LAKE COOK ROAD SUITE 330 DEERFIELD IL 60015 990 2023-07-01 366102182 LEUKEMIA RESEARCH FOUNDATION LEUK 8474240600 191 WAUKEGAN ROAD 105 NORTHFIELD IL 60093 KEVIN RADELET EXECUTIVE DIRECTOR 8474240600 2024-10-23 1 1 MARCY STEINDLER P00573131 8472673400 2023 2024-10-15 13:58:12Z KEVIN RADELET 191 WAUKEGAN ROAD 105 NORTHFIELD IL 60093 3017344 0 X WWW.LEUKEMIARF.ORG X 1951 IL TO CURE LEUKEMIA BY FUNDING INNOVATIVE RESEARCH, AND TO SUPPORT PATIENTS AND FAMILIES. 14 14 7 500 0 0 4111876 2349551 0 0 81224 141261 144 4798 4193244 2495610 2440416 1657011 0 0 730188 682621 0 0 235611 411881 270439 3582485 2610071 610759 -114461 6864748 6882073 2716288 2795411 4148460 4086662 X TO CURE LEUKEMIA BY FUNDING INNOVATIVE RESEARCH, AND TO SUPPORT PATIENTS AND FAMILIES. 0 0 1659167 1530888 RESEARCH GRANTS - IN FISCAL YEAR 2024, 10 RESEARCH GRANTS WERE AWARDED TO NEW INVESTIGATORS STUDYING LEUKEMIA OR MDS FROM US-BASED AND INTERNATIONAL MEDICAL INSTITUTIONS. EACH GRANT AWARD IS $150,000 OVER A TWO-YEAR PERIOD, WITH TOTAL RESEARCH FUNDING OF $1.5 MILLION. RESEARCH GRANT AWARDS WERE SELECTED BASED ON RECOMMENDATIONS FROM THE FOUNDATION'S INDEPENDENT MEDICAL ADVISORY BOARD AFTER A RIGOROUS GRANT REVIEW PROCESS. 274243 PATIENT EDUCATION AND SUPPORT - PATIENT EDUCATION AND SUPPORT SEVEN PATIENT EDUCATION PROGRAMS WERE PROVIDED FOR PATIENTS AND CAREGIVERS IN FISCAL YEAR 2024. TOPICS WERE SELECTED BASED ON EVALUATION RESPONSES FROM PAST EDUCATION PROGRAMS AND FEEDBACK FROM PATIENT ADVISORY COMMITTEE MEMBERS. PROGRAMS INCLUDED THE ANNUAL NEW & EMERGING TREATMENTS SERIES (4 WEBINARS), LEUKEMIA Q&A (CHRONIC AND ACUTE WEBINARS) AND A WEBINAR FOCUSED ONCLINICAL TRIALS. A TOTAL OF 916 PARTICIPANTS REGISTERED FOR THE PATIENT EDUCATION PROGRAMS AND FEEDBACK WAS VERY POSITIVE WITH 91% OF THOSE WHO RESPONDED TO A POST-EVENT SURVEY REPORTING THAT THEY WOULD ATTEND A FUTURE EVENT. 88% RATED THE PROGRAM CONTENT VERY GOOD OR EXCELLENT AND OVER 74% SAID THEY WOULD USE THE INFORMATION THEY LEARNED IN THEIR TREATMENT DECISIONS. 195176 126123 PATIENT GRANT PROGRAM - IN FISCAL YEAR 2024, 85 FINANCIAL ASSISTANCE GRANTS OF UP TO $1,500 WERE AWARDED TO PATIENTS. THIS NEED-BASED PROGRAM ASSISTS LEUKEMIA PATIENTS AND THEIR FAMILIES BY EASING THE FINANCIAL BURDEN THAT COMES WITH A LEUKEMIA DIAGNOSIS SO THE FOCUS CAN BE ON HEALTH AND TREATMENT. GRANT AWARDS CAN BE USED FOR ANY EXPENSE, INCLUDING MEDICAL BILLS, MEDICATIONS, TRANSPORTATION AND LODGING EXPENSES, RENT, FOOD, AND MORE. 2128586 1 1 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 0 0 0 1 1 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 2 0 1 7 1 0 0 0 0 0 0 0 0 0 0 0 0 X 14 14 0 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 0 0 CA FL GA IL MD MA MI MT NJ NC NY OK TN RI OR UT VA WV WI NV CO CT ME MO OH TX WA MT NM AL PA ND KS KY MS MN X X ARLEEN BOUDART 8474240600 191 WAUKEGAN ROAD SUITE 105 NORTHFIELD IL 60093 BLAKE BRANDWEIN PRESIDENT 0.50 X X 0 0 0 GERALD BRIN TREASURER 0.50 X X 0 0 0 PATTY MIX SECRETARY 0.50 X X 0 0 0 ROBERT GRABEMANN GENERAL COUNSEL 0.50 X 0 0 0 TAMAR UZIEL AT LARGE MEMBER 0.50 X 0 0 0 JAIME MORAN AT LARGE MEMBER 0.50 X 0 0 0 JOE GARBARSKI AT LARGE MEMBER 0.50 X 0 0 0 TODD HOLMES AT LARGE MEMBER 0.50 X 0 0 0 FRANK MARTINEZ AT LARGE MEMBER 0.50 X 0 0 0 LARRY MIX AT LARGE MEMBER 0.50 X 0 0 0 RANDI SCHULLO AT LARGE MEMBER 0.50 X 0 0 0 STEVE WILENSKY AT LARGE MEMBER 0.50 X 0 0 0 SAVYON AMIT VICE PRESIDENT 0.50 X X 0 0 0 RONG CHEN AT LARGE MEMBER 0.50 X 0 0 0 KEVIN RADELET EXECUTIVE DIRECTOR 37.50 X 153786 0 19349 153786 0 19349 1 0 1 0 0 18211 2331340 26363 2349551 142447 142447 520548 521734 -1186 -1186 -1186 OTHER INCOME 900099 4798 4798 4798 2495610 4798 0 141261 1377801 1377801 126123 126123 153087 153087 181750 98145 36350 47255 403930 218122 80786 105022 13600 7344 2720 3536 41534 22428 8307 10799 41807 22576 8361 10870 24672 24672 2875 2875 10968 10968 35569 14330 18414 2825 51691 41785 4307 5599 67008 19536 37794 9678 13814 13214 261 339 331 179 66 86 7054 1997 4066 991 FUNDRAISING CAMPAIGNS 33570 6668 26902 PUBLIC RELATIONS 8460 2395 4876 1189 MISCELLANEOUS 7548 1571 575 5402 MARKETING 4499 4499 2380 1285 476 619 2610071 2128586 245874 235611 2275696 2780311 3091729 1960396 973939 305038 10131 8512 136168 134513 325 1655 1306806 512928 519355 6864748 6882073 87665 14300 2517535 2685682 111088 95429 2716288 2795411 X 3016247 3555696 1132213 530966 4148460 4086662 6864748 6882073 X -114461 10892 41771 X 0 1 X 1 0 X 2598095 2574542 2923993 4111876 2349551 14558057 2598095 2574542 2923993 4111876 2349551 14558057 1550709 13007348 22499 14471 6619 90927 142447 276963 3755 144 4798 8697 14843717 0.87630 0.88230 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 86084 1514 699 86899 85526 688 130 86084 85360 305 139 85526 84594 1220 454 85360 83945 1338 689 84594 1.00000 0 0 99358 98028 1330 36810 36485 325 1655 SECURITY DEPOSIT 4663 BENEFICIAL INTEREST IN TRUST 424067 OPERATING RIGHT-OF-USE ASSETS 90625 519355 OPERATING LEASE LIABILITIES 95429 95429 X 2545398 37208 15455 52663 2492735 2875 2875 2495610 2607196 0 2607196 2875 2875 2610071 PART V, LINE 4: THE EARNINGS OF THE FUND ARE TO BE USED TO PROVIDE ASSISTANCE TO PATIENTS AND THEIR FAMILIES AND TO FUND MEDICAL RESEARCH. PART X, LINE 2: THE FINANCIAL STATEMENT EFFECTS OF A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN ARE RECOGNIZED IN THE FINANCIAL STATEMENTS WHEN IT IS MORE LIKELY THAN NOT, BASED ON THE TECHNICAL MERITS, THAT THE POSITION WILL BE SUSTAINED UPON EXAMINATION. AS OF JUNE 30, 2024, THE FOUNDATION HAD NO UNCERTAIN TAX POSITIONS THAT QUALIFY FOR RECOGNITION OR DISCLOSURE IN THE FINANCIAL STATEMENTS. PART XI, LINE 2D - OTHER ADJUSTMENTS: CANCELLATION OF GRANTS 15,455. 1 EAST ASIA AND THE PACIFIC 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 150000 0 0 0 0 0 0 150000 0 150000 EAST ASIA AND THE PACIFIC NEW INVESTIGATOR RESEARCH GRANT 153087 WIRE TRANSFER 0 1 0 0 0 0 0 0 0 PART I, LINE 2: THE FINAL SCIENTIFIC REPORT SHOULD BE RECEIVED WITHIN 30 DAYS OF COMPLETION OF THE PROJECT. GRANTEES ARE RQUIRED TO COMPLETE THE FINAL SCIENTIFIC REPORT FORM AND E-MAIL THE FOUNDATION WITH A BRIEF SCIENTIFIC SUMMARY, A BRIEF LAY SUMMARY, AND A LIST OF ANY RESULTING PUBLICATIONS. 1 EMORY UNIVERSITY 1599 CLIFTON ROAD NE 4TH FLOOR ATLANTA GA 30322 580566256 501(C)(3) 150000 0 NEW INVESTIGATOR RESEARCH GRANT ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE BUSTAVE L LEVY PLACE BOX 1075 NEW YORK NY 10029 136171197 501(C)(3) 150000 0 NEW INVESTIGATOR RESEARCH GRANT INDIANA UNIVERSITY 509 E 3RD STREET BLOOMINGTON IN 47401 356001673 SECTION 115 150000 0 NEW INVESTIGATOR RESEARCH GRANT SEATTLE CHILDREN'S HOSPITAL 1900 NINTH AVE M/S 818-S SEATTLE WA 98101 910564748 501(C)(3) 150000 0 NEW INVESTIGATOR RESEARCH GRANT UNIVERSITY OF MIAMI HEALTH SYSTEMS 1531 BRESCIA AVE SUITE 124 CORAL GABLES FL 33146 590624458 501(C)(3) 150000 0 NEW INVESTIGATOR RESEARCH GRANT THE JACKSON LABORATORY FOR GENOMIC MEDICINE 10 DISCOVERY DRIVE FARMINGTON CT 06032 010211513 501(C)(3) 150000 0 NEW INVESTIGATOR RESEARCH GRANT COLUMBIA UNIVERSITY 733 NORTH BROADWAY SUITE 117 BALTIMORE MD 21205 135598093 501(C)(3) 150000 0 NEW INVESTIGATOR RESEARCH GRANT WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVE NEW YORK NY 10065 131623978 501(C)(3) 150000 0 NEW INVESTIGATOR RESEARCH GRANT MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501(C)(3) 150000 0 NEW INVESTIGATOR RESEARCH GRANT 9 0 MEDICAL FINANCIAL ASSISTANCE 85 126123 PART I, LINE 2: THE FINAL SCIENTIFIC REPORT SHOULD BE RECEIVED WITHIN 30 DAYS OF COMPLETION OF THE PROJECT. GRANTEES ARE REQUIRED TO COMPLETE THE FINAL SCIENTIFIC REPORT FORM AND E-MAIL THE FOUNDATION WITH A BRIEF SCIENTIFIC SUMMARY, A BRIEF LAY SUMMARY, AND A LIST OF ANY RESULTING PUBLICATIONS. X X X 0 0 0 0 0 0 0 0 0 KEVIN RADELET EXECUTIVE DIRECTOR 153786 0 0 0 0 0 4614 0 14735 0 173135 0 0 0 X 3 26363 FMV 0 0 0 PART I, COLUMN (B): THE NUMBER OF DONATIONS IS DISCLOSED. FORM 990, PART VI, SECTION B, LINE 11B THE FINANCE DIRECTOR AND EXECUTIVE DIRECTOR REVIEW FORM 990. THE FINAL DRAFT OF FORM 990 IS MADE AVAILABLE TO ALL BOARD MEMBERS PRIOR TO FILING. MEMBERS ARE NOTIFIED THAT FORM 990 HAS BEEN POSTED AND THEY CAN ACCESS A URL AND PUT IN THEIR PASSWORD TO VIEW THE DOCUMENT. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY IS REVIEWED ANNUALLY AND MONITORED AS POTENTIAL REFERENCE AND/OR ACTION IS CALLED FOR. FORM 990, PART VI, SECTION B, LINE 15A THE EXECUTIVE DIRECTOR'S SALARY IS DETERMINED BY A COMPENSATION SURVEY. WE USE A WRITTEN EMPLOYMENT CONTRACT THAT IS APPROVED BY THE BOARD FORM 990, PART VI, SECTION C, LINE 19 WE MAKE OUR GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY AVAILABLE UPON REQUEST. THE FINANCIAL STATEMENTS ARE AVAILABLE ONLINE AND UPON REQUEST. FORM 990, PART XI, LINE 9: CHANGE IN VALUE OF BENEFICIAL INTEREST IN TRUST 26,316. CANCELLATION OF GRANTS 15,455.